Ziconotide vs Calcitonin
Head-to-head comparison of Ziconotide (ω-Conotoxin MVIIA (ziconotide)) and Calcitonin (Salmon Calcitonin) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Ziconotide | Calcitonin |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | ω-Conotoxin MVIIA (ziconotide) | Salmon Calcitonin |
| Molecular Weight | 2639.1 Da | 3431.9 Da |
| Half-Life | approximately 4.5 hours | about 10-15 minutes |
| Amino Acids | 25 | 32 |
| Typical Dose | 0.5-19.2 mcg/day | 100 IU/day SC or 200 IU/day intranasal |
| Route | Intrathecal | Intranasal/Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 500 | 350 |
| Research Status | Approved | Approved |
Ziconotide Benefits
- ✓strong non-opioid analgesia
- ✓effective for refractory neuropathic pain
- ✓opioid-sparing option
- ✓intrathecal delivery allows targeted action
Calcitonin Benefits
- ✓bone pain relief
- ✓short-term analgesic effect
- ✓may reduce opioid requirement
- ✓useful in osteoporotic fracture pain
Ziconotide Dosing
start 0.5 mcg/day intrathecal|titrate by 0.5 mcg/day no more than 2 times weekly|max 19.2 mcg/day in labeling
Calcitonin Dosing
100 IU subcutaneous daily|200 IU intranasal daily|short-term use in acute pain settings
Ziconotide Side Effects
- ⚠dizziness
- ⚠confusion
- ⚠ataxia
Calcitonin Side Effects
- ⚠nausea
- ⚠flushing
- ⚠rhinitis
Research Overview
Ziconotide
Clinical studies and post-marketing data support ziconotide as an analgesic for severe chronic pain that does not respond to conventional therapy. Research focuses on balancing analgesic efficacy with neuropsychiatric tolerability and careful dose titration.
Calcitonin
Calcitonin has been evaluated in randomized trials and reviews for pain associated with vertebral compression fractures and other bone-related conditions. The signal is strongest for short-term analgesia rather than long-term chronic pain control.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.